Filing Details

Accession Number:
0001209191-21-019268
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-09 19:26:01
Reporting Period:
2021-03-08
Accepted Time:
2021-03-09 19:26:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1341011 Annette North C/O Turning Point Therapeutics, Inc.
10628 Science Center Drive, Ste. 200
San Diego CA 92121
Evp, General Counsel & Secty. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-08 20,000 $17.00 26,483 No 4 M Direct
Common Stock Disposition 2021-03-08 500 $103.30 25,983 No 4 S Direct
Common Stock Disposition 2021-03-08 4,810 $109.09 21,173 No 4 S Direct
Common Stock Disposition 2021-03-08 9,419 $109.89 11,754 No 4 S Direct
Common Stock Disposition 2021-03-08 4,571 $110.77 7,183 No 4 S Direct
Common Stock Disposition 2021-03-08 700 $111.69 6,483 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-03-08 20,000 $0.00 20,000 $17.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
175,491 2029-04-14 No 4 M Direct
Footnotes
  1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
  2. The weighted average sale price for the transaction reported was $109.09, and the range of prices were between $108.46 and $109.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. The weighted average sale price for the transaction reported was $109.89, and the range of prices were between $109.47 and $110.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. The weighted average sale price for the transaction reported was $110.77, and the range of prices were between $110.48 and $111.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. The weighted average sale price for the transaction reported was $111.69, and the range of prices were between $111.52 and $111.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  6. One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested.